openPR Logo
Press release

Clinical Trials: A Complete PDF Guide [PDF]

01-24-2024 02:12 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: The Insight Partners

Clinical Trials Market

Clinical Trials Market

The report highlights trends prevailing in the market, and the factors driving and hindering the clinical trials market growth. The growth of the global clinical trials market is attributed increasing adoption and outsourcing of clinical trials, and the flourishing pharmaceutical industry with increasing R&D activities. However, the expensive and time-consuming process restricts the clinical trials market growth.

Get Sample PDF Details at: https://www.theinsightpartners.com/sample/TIPRE00006203?utm_source=OpenPR&utm_medium=10776

Based on phase, the clinical trials market is categorized into Phase I, Phase II, Phase III, and Phase IV. The Phase III segment held the largest market share in 2022, and it is estimated to register the highest CAGR during the forecast period. The Phase III is most expensive phase as it involves a vast number of subjects. The stage assists in determining the short-term and long-term efficacy of the active pharmaceutical ingredients. Thus, the assessment is done to know the total and associated therapeutic values of formulated drug. It also assists in complying with FDA standards that help introduce the drug into the market and complete the required licensing applications. In March 2023, AbbVie announced topline results from a Phase 2 study of RINVOQ, 30 mg (upadacitinib) when given alone or in combination therapy with a Bruton's Tyrosine Kinase inhibitor, once daily in patients with moderately to severely active systemic lupus erythematosus (SLE). Based on the results, AbbVie is advancing its clinical program of upadacitinib in SLE patients to Phase 3. Therefore, the successful transition from the Phase II to Phase III studies favors the growth of the clinical trials market for the Phase III segment.

Based on the study design, the clinical trials market is segmented into interventional, observational, and expanded access. In terms of phase, the market is segmented Phase I, Phase II, Phase III, and Phase IV. The clinical trials market, by indication, is segmented autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular disease, and others. Based on geography, the clinical trials market is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

IQVIA Holdings Inc, Parexel International Corp, IXICO Plc, Charles River Laboratories International Inc, ICON Plc, WuXi AppTec Co Ltd, SGS SA, Syneos Health Inc, SIRO Clinpharm Pvt Ltd, Thermo Fisher Scientific Inc, and Laboratory Corp of America Holdings are the leading companies operating in the global clinical trials market.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Ankit Mathur
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About The Insight Partners:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Clinical Trials: A Complete PDF Guide [PDF] here

News-ID: 3361884 • Views:

More Releases from The Insight Partners

Armor Materials Market Demand, Share & Growth by 2034
Armor Materials Market Demand, Share & Growth by 2034
Armor materials are specialized substances designed to protect individuals and assets from various forms of threats, including ballistic impacts, blasts, and other hazardous conditions. These materials are utilized in a wide range of applications, including personal protective equipment, military vehicles, aerospace components, and civil infrastructure. The demand for advanced armor solutions is driven by the need for enhanced safety and security in both military and civilian contexts. To Get Sample Copy
Plant based Foods Market Size is Expected to Reach US$ 112.98 Billion by 2034 from US$ 50.40 Billion in 2025 at a CAGR of 9.38%
Plant based Foods Market Size is Expected to Reach US$ 112.98 Billion by 2034 fr …
The Plant based Foods Market is poised for remarkable growth, driven by increasing consumer awareness regarding health, sustainability, and ethical food choices. According to the latest market research by The Insight Partners, the Plant based Foods Market is projected to grow from US$ 50.40 Billion in 2025 to US$ 112.98 Billion by 2034, registering a CAGR of 9.38% during the forecast period from 2026 to 2034. The rising popularity of
Multivitamin Tablets and Capsules Market to Reach US$ 49.37 Billion by 2034 at a CAGR of 3.90%
Multivitamin Tablets and Capsules Market to Reach US$ 49.37 Billion by 2034 at a …
The multivitamin tablets and capsules market is witnessing consistent growth, driven by rising consumer awareness regarding preventive healthcare, increasing demand for dietary supplements, and expanding health and wellness trends across developed and emerging economies. According to The Insight Partners, the global multivitamin tablets and capsules market size is projected to grow from US$ 34.99 billion in 2025 to US$ 49.37 billion by 2034, registering a CAGR of 3.90% during the
Global Green (Vegetative) Roofing Market Worth US$ 12.46 Billion by 2034, Growing at a CAGR of 16.54% | The Insight Partners
Global Green (Vegetative) Roofing Market Worth US$ 12.46 Billion by 2034, Growin …
The global Green (Vegetative) Roofing Market is poised for remarkable growth as sustainability initiatives, urban greening programs, and energy-efficient construction practices continue to gain momentum worldwide. According to the latest market analysis by The Insight Partners, the market is expected to grow from US$ 3.14 billion in 2025 to US$ 12.46 billion by 2034, registering a robust CAGR of 16.54% during the forecast period of 2026-2034. Get Sample Copy of Report

All 5 Releases


More Releases for Phase

The Quiet Phase Is Almost Over: BlazPay's Phase 8 Presale Is 90% Sold Out
There's a moment in every successful crypto project that most people miss. It's not the launch. It's not the exchange listing. It's the final stretch of the presale - when the numbers are real, the momentum is visible, and the entry price is about to change forever. BlazPay is at that moment right now. Phase 8 of the BlazPay presale is 90.4% sold. Over 267 million of 295 million BLAZ tokens
Single-Phase and Three-Phase Amplifiers: An Innovative Solution to Overcome Sing …
I. Rural Power Grid Upgrades: Solving Power Supply Challenges in Remote AreasChallenges:In remote rural areas, long supply radii and scattered users, combined with single-phase power supply, lead to unstable end-point voltages and insufficient power, making it difficult to meet the electricity demands of modern home appliances and agricultural machinery.Benefits:Improved Voltage Quality: By converting single-phase power into balanced three-phase output, line losses are reduced, resolving the issue of low end-point voltages.Expanded
Clinical Trials by Phase (Phase I, Phase II, Phase III, Phase IV) Market Forecas …
A clinical trial is a research study, where a group of people is given a test or treatment. Clinical trials study the safety and efficacy of tests and treatments. If the test or treatment is safe and meets regulatory requirements, then it is approved as a standard of care. Download Sample Copy at https://www.theinsightpartners.com/sample/TIPRE00006203/?utm_source=OpenPR&utm_medium=10379 Key Players Analysis:  IQVIA  Parexel International Corporation  Charles River Laboratories  ICON plc  SGS SA  Chiltern International Ltd  Syneos Health  PRA Health Sciences  Wuxi AppTec Inc  Pharmaceutical Product Development,
Digital Phase Shifters Market
Digital Phase Shifters Market A recently identified vacuum in the literature about the creation of digital phase shifters for modern communication systems is attempted to be filled in the book Design of Digital Phase Shifters for Multipurpose Communication Systems. By significantly reducing RF power consumption and improving noise immunity, directed beams enhance the development of new-generation mobile communication systems. In this regard, digital phase shifters in particular, which are part
COVID-19 - Pipeline Analysis 2020 for Global Market | Emphasis on Products cover …
COVID-19 (also known as Anderson COVID-19)?is a viral disease caused by RNA virus, SARS-CoV-2 or commonly known as corona virus. These viruses can cause respiratory, enteric, hepatic, and neurologic diseases. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other
HIV Vaccines Market Perceive Aggrandized Growth at a CAGR of 11.48% Till 2023 | …
HIV Vaccines Market Report Added on MarketResearchFuture.com with Overall Analysis. Key developments and Strategies Cover in this Report. The Market for Expected to Grow Globally Over the CAGR of 5 % During the Period 2018 to 2027 from USD 2,702.3 Billion in 2027. HIV Vaccines Market - Segmentation The global HIV vaccines market has been segmented on the basis of basis of antibiotics, type, and lastly, region. Antibiotics have been segmented into dicloxacillin,